E2 Achieves Dual FDA Clearances for Innovative Hēlo® Platform to Combat Pulmonary Embolism

E2 Secures Dual FDA Clearances for the Hēlo® Platform

Endovascular Engineering, Inc. (E2) has reached a critical milestone in medical technology by obtaining 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Hēlo® Thrombectomy System alongside the Hēlo® Return system. This pioneering advancement is aimed at tackling venous thromboembolism (VTE) efficiently, a significant health issue that leads to substantial cardiovascular complications every year.

A New Era in Pulmonary Embolism Treatment

The Hēlo® Platform is a game-changer in the realm of mechanical thrombectomy, a procedure vital for the treatment of pulmonary embolism (PE). Designed with the precise needs of physicians in mind, Hēlo enables streamlined operations while ensuring enhanced performance. The platform integrates a dual-action approach that combines continuous aspiration with mechanical disruption, significantly improving clot removal efficiency and reducing blood loss. This feature was effectively demonstrated in the ENGULF IDE study, which showcased remarkable outcomes with the system, highlighting its unequivocal potential in reshaping PE treatment.

With pulmonary embolism remaining one of the leading causes of cardiovascular mortality and morbidity, the demand for effective and efficient treatment methods is escalating. Eric Secemsky, MD, a key figure in vascular intervention, commented on the innovative nature of the Hēlo® System, stating, “The treatment of PE with mechanical thrombectomy is rapidly evolving as emerging data and new technologies continue to shape the field.” He emphasized that the system effectively meets real-world challenges faced during such procedures, enhancing accessibility for a broader patient demographic.

Innovative Design Features

The Hēlo® Thrombectomy System features a lower profile design that facilitates navigation through smaller vessels, enhancing its usability and effectiveness in diverse clinical situations. It incorporates a 15F crossing profile along with steerable navigation, allowing physicians precise control for maneuvering within the pulmonary vasculature.

Moreover, the system innovatively utilizes a 24F clot ingestion funnel at the catheter's distal end. This design optimally aids in the aspiration and remodeling of clots—a crucial factor in the success of PE interventions. Complementing the thrombectomy system is the Hēlo® Return, which integrates blood return capabilities, realized in clinical tests during the ENGULF study. This remarkable combination leads to nearly zero blood loss during procedures, substantially improving patient outcomes.

A Collaborative Effort Towards Better Health Solutions

E2's accomplishment stems from years of dedicated research and collaboration with healthcare professionals, ensuring that their products align closely with the needs and challenges faced in interventional procedures. Dan Rose, CEO of E2, stated, “This milestone is the culmination of years of focused innovation to create a unique and complete platform that addresses the procedural limitations physicians currently experience when treating PE.”

Beyond the unique technological features, the FDA clearances pave the way for increased market access, enabling E2 to promote their solutions to a wider range of healthcare providers and patients, ultimately enhancing treatment availability for those suffering from PE.

Conclusion

The dual FDA clearances for the Hēlo® platform mark a significant step toward revolutionizing pulmonary embolism treatment. By addressing critical procedural challenges of clot removal while maintaining patient safety and reducing complexity, E2 is set to change the landscape of VTE interventions. As clinical data continues to support the efficacy and safety of the Hēlo® system, health professionals now have more effective tools at their disposal, offering hope to countless patients facing the serious threat of pulmonary embolism.

For further information on E2 and the Hēlo® platform, please visit E2's website or follow them on LinkedIn.